Abstract: Objective To summarize the clinical features and to evaluate outcomes and to assess therapeutic effects in 26 children and adolescents with Burkitt's leukemia treated with revised LMB 89 protocol in China.Methods From January 2010 to April 2015, 26 hospitalized children and adolescents with Burkitt's leukemia were enrolled into this study. Staging was based on clinical evaluation and was defined by the St. Jude staging system. All patients were confirmed to have Burkitt's leukemia and mature B blast > 25% in marrow that diagnosed by MICM system and biopsy of marrow. The 26 patients were treated with C group of the revised LMB 89 protocol.All analyses were performed by the statistical program SPSS.Results Of the 26 Burkitt's leukemia patients, 24 were male and 2 were female.The median age was 7.8 years (range from 3 years to 13 years) at the time of diagnosis.In terms of clinical presentation, 88% had abdominal bulky lymphoma involvement; in 62% of the patients maxillofacial region was involved, 27% had testis involvement, 69% had severe tumor lysis syndrome. All patients were followed up. The overall survival (OS) and the 2-year event-free survival was 76.9% respectively at a median follow-up of 35 months.All patients suffered from IV degree marrow suppression and sever infection. Two patients died from sepsis in the early 2 course of chemotherapy because of severe marrow suppression, and no child died from TLS. Three patients had early relapse after treatment was finished.Conclusion Childhood Burkitt's leukemia in our study was more frequently seen in male school aged children.Revised LMB 89 protocol used for Burkitt's leukemia is effective and well tolerated if the early TLS could be controlled.The overall prognosis is worse than that of other group Burkitt's lymphoma because of early severe persistent marrow suppression complicated with sepsis.The early relapse is still a challenge.

Key words: Burkitt's lymphoma, leukemia, child, therapies, investigational